What it is
Adamax is a placeholder name for a Semax-derived nootropic idea. No PubMed-backed protocol evidence is established.
Evidence boundary
No validated human dosing protocol is available. Do not treat the schedule below as established fact.
Trial evidence
None verified.
Preparation and measurement
No source-backed vial or BAC convention verified.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Cycle | 250 mcg | 5 U (0.05 mL) | Daily during cycle | 1.75 mg/week |
Cycle
- Dose
- 250 mcg
- Draw / measure
- 5 U (0.05 mL)
- Frequency
- Daily during cycle
- Weekly total
- 1.75 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Standard (250 mcg/day): Typical research-cycle dose.
-
Cycle: 4-week active, 2-week break.
-
Source quality
-
Exact product identity
-
Whether the name is being used as shorthand for a different peptide
Practical rules
- Verify the exact compound name before using any dosing advice.
- No source-backed record establishes a validated dosing protocol for Adamax.
Related protocols
Semax Peptide Protocol & DosingSelank Peptide Protocol & DosingCerebrolysin Peptide Protocol & DosingPE-22-28 Peptide Protocol & DosingDihexa Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for Adamax Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes